Holen Sie sich die Stockscreener-App
15.88
1.34%
0.21
Viridian Therapeutics Inc Aktie (VRDN) Neueste Nachrichten
Viridian Therapeutics’ SWOT analysis: promising TED treatment stock faces pivotal year - Investing.com
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Shares Purchased by California State Teachers Retirement System - Defense World
Viridian Therapeutics: The Song Remains The Same (NASDAQ:VRDN) - Seeking Alpha
Transcript : Viridian Therapeutics, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 08 - marketscreener.com
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $2.22 Million Stake in Viridian Therapeutics, Inc. (NASDAQ:VRDN) - Defense World
Where are the Opportunities in (VRDN) - news.stocktradersdaily.com
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | VRDN Stock News - GuruFocus
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Viridian Therapeutics shares fall as Q1 loss narrows, revenue beats By Investing.com - Investing.com Nigeria
Ameriprise Financial Inc. Increases Stock Position in Viridian Therapeutics, Inc. (NASDAQ:VRDN) - Defense World
Viridian Therapeutics to Participate in Upcoming June 2025 Investor Conferences - BioSpace
Viridian Therapeutics to Participate in Upcoming June Investor C - GuruFocus
Viridian Therapeutics to Participate in Upcoming June Investor Conferences - Business Wire
Bank of America Corp DE Grows Position in Viridian Therapeutics, Inc. (NASDAQ:VRDN) - Defense World
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Buys 13,990 Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN) - Defense World
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Stock Holdings Increased by Nuveen Asset Management LLC - Defense World
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Shares Sold by Millennium Management LLC - Defense World
Needham & Company LLC Reiterates “Buy” Rating for Viridian Therapeutics (NASDAQ:VRDN) - Defense World
Viridian Therapeutics’ veligrotug shows durability in Phase III TED trial - Yahoo Finance
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Receives $36.70 Average Target Price from Analysts - Defense World
Veligrotug Shows Durability for Thyroid Eye Disease in Phase 3 Trial Results - HCPLive
Viridian Therapeutics’ SWOT analysis: promising TED treatment stock faces key catalysts - Investing.com Nigeria
Viridian Therapeutics (VRDN) Maintains Stable Outlook with Buy Rating | VRDN Stock News - GuruFocus
Viridian Therapeutics: Buy Rating Affirmed on Promising Phase III Results and Strategic Growth Plans - TipRanks
Viridian Therapeutics Announces Positive Long-Term Durability Data from the Veligrotug Phase 3 THRIVE Clinical Trial in Patients with Active Thyroid Eye Disease (TED) - BioSpace
Viridian Therapeutics Announces Positive Long-Term Durability Da - GuruFocus
Viridian's (VRDN) Veligrotug Shows Promising Long-Term Results in TED Treatment | VRDN Stock News - GuruFocus
Viridian Announces Positive Long-Term Data From Phase 3 Trial Of Veligrotug In Thyroid Eye Disease - Nasdaq
Viridian Therapeutics Announces Positive Long-Term Durability Data from the Veligrotug Phase 3 THRIVE Clinical Trial in Patients with Active Thyroid Eye Disease (TED) | VRDN Stock News - GuruFocus
Northern Trust Corp Boosts Stock Position in Viridian Therapeutics, Inc. (NASDAQ:VRDN) - Defense World
Dimensional Fund Advisors LP Sells 271,156 Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN) - Defense World
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Shares Bought by The Manufacturers Life Insurance Company - Defense World
Viridian Therapeutics (VRDN) to Release Quarterly Earnings on Wednesday - Defense World
Q2 EPS Estimate for Viridian Therapeutics Lowered by Analyst - Defense World
Wedbush Boosts Earnings Estimates for Viridian Therapeutics - Defense World
Q2 EPS Estimate for Viridian Therapeutics Reduced by Analyst - Defense World
B. Riley Boosts Earnings Estimates for Viridian Therapeutics - Defense World
Needham & Company LLC Cuts Viridian Therapeutics (NASDAQ:VRDN) Price Target to $36.00 - The AM Reporter
JMP Securities Cuts Viridian Therapeutics (NASDAQ:VRDN) Price Target to $38.00 - Defense World
Royal Bank of Canada Cuts Viridian Therapeutics (NASDAQ:VRDN) Price Target to $45.00 - Defense World
Q1 Earnings Estimate for VRDN Issued By HC Wainwright - Defense World
The Goldman Sachs Group Issues Pessimistic Forecast for Viridian Therapeutics (NASDAQ:VRDN) Stock Price - Defense World
Needham & Company LLC Lowers Viridian Therapeutics (NASDAQ:VRDN) Price Target to $36.00 - Defense World
Viridian Therapeutics Receives FDA Breakthrough Therapy Designation for Veligrotug for the Treatment of Thyroid Eye Disease (TED) - BioSpace
Decoding Viridian Therapeutics Inc (VRDN): A Strategic SWOT Insi - GuruFocus
What 5 Analyst Ratings Have To Say About Viridian Therapeutics - Benzinga
Viridian Therapeutics, Inc. (VRDN) Reports Q1 Loss, Lags Revenue Estimates - MSN
FDA Grants Breakthrough Therapy Status to Viridian's (VRDN) Veligrotug | VRDN Stock News - GuruFocus
Viridian Therapeutics Receives FDA Breakthrough Therapy Designation for Veligrotug for the Treatment of Thyroid Eye Disease (TED) | VRDN Stock News - GuruFocus
Viridian Therapeutics (VRDN) Target Price Adjusted by RBC Capita - GuruFocus
Goldman Sachs Adjusts Price Target for VRDN, Maintains Buy Ratin - GuruFocus
Goldman Sachs Adjusts Price Target for VRDN, Maintains Buy Rating | VRDN Stock News - GuruFocus
Viridian Therapeutics (VRDN) Price Target Update by JMP Securities | VRDN Stock News - GuruFocus
Viridian Therapeutics (VRDN) Price Target Reduced Amid Market Concerns | VRDN Stock News - GuruFocus
Needham Maintains Buy Rating on Viridian Therapeutics (VRDN) | V - GuruFocus
Needham Maintains Buy Rating on Viridian Therapeutics (VRDN) | VRDN Stock News - GuruFocus
Viridian Therapeutics price target lowered to $38 from $42 at Citizens JMP - TipRanks
Thyroid Eye Disease Market Top Companies StudyHorizon - openPR.com
1.91%
1.17%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):